GlassScriptPhysician profile
Raphael I Kieval
NPI 1730155029
$145,811.38
in general payments reported to CMS, 2019-2025
47 companies · $33K in 2025
The $33K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $5,019 · 2021: $4,102 · 2022: $21K · 2023: $37K · 2024: $29K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Food and Beverage: $17K · Travel and Lodging: $1,835 · Consulting Fee: $425 · Education: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,489.50 |
| Food and Beverage | $17,220.66 |
| Travel and Lodging | $1,834.79 |
| Consulting Fee | $425.00 |
| Education | $358.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $74,409.96 | 2019-2025 | |
| Janssen Biotech, INC. | $50,987.27 | 2019-2025 | Simponi Aria, Tremfya, Remicade |
| Amgen INC. | $3,485.95 | 2019-2025 | Evenity, Krystexxa, Enbrel |
| Ucb, INC. | $2,011.18 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $1,888.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,511.03 | 2019-2025 | |
| Lilly USA, LLC | $1,373.00 | 2019-2024 | Taltz, Zepbound |
| Janssen Scientific Affairs, LLC | $1,160.00 | 2023-2024 | Simponi Aria, Stelara, Tremfya |
| Astrazeneca Pharmaceuticals LP | $1,125.02 | 2022-2025 | Saphnelo, Evusheld |
| Mallinckrodt Hospital Products INC. | $903.64 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $861.97 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $838.48 | 2019-2025 | Orencia, Sotyktu |
| Sandoz INC. | $612.82 | 2023-2025 | Hyrimoz, Jubbonti |
| Horizon Therapeutics Plc | $550.35 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $441.54 | 2020-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $381.31 | 2019-2023 | Actemra, Rituxan |
| Ani Pharmaceuticals, INC. | $360.99 | 2022-2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.12 | 2019-2024 | Cyltezo, Ofev |
| Hikma Pharmaceuticals USA | $311.48 | 2019-2023 | Mitigare |
| Celgene Corporation | $304.12 | 2019 | |
| Organon LLC | $273.65 | 2023-2025 | Hadlima, Renflexis |
| Alexion Pharmaceuticals, INC. | $197.27 | 2020-2024 | Strensiq, Ultomiris |
| Fresenius Kabi USA, LLC | $180.24 | 2023-2025 | Idacio, Tyenne |
| Regeneron Healthcare Solutions, INC. | $178.76 | 2019 | |
| Radius Health, INC. | $176.67 | 2019-2023 | Tymlos |
| Sobi, INC | $174.19 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $118.91 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2023 | |
| Tersera Therapeutics LLC | $74.18 | 2019-2025 | Quzyttir |
| Kiniksa Pharmaceuticals, LTD. | $64.24 | 2021-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $56.37 | 2019-2020 | |
| Bioventus LLC | $47.36 | 2019-2023 | Durolane |
| Pacira Pharmaceuticals Incorporated | $45.12 | 2023 | Zilretta |
| Kyowa Kirin, INC. | $43.68 | 2024 | Crysvita |
| Kiniksa Pharmaceuticals International, Plc | $30.88 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $29.90 | 2022-2023 | Seglentis |
| Zimmer Biomet Holdings, INC. | $27.61 | 2019 | |
| Invivyd INC | $23.78 | 2025 | Pemgarda |
| Alvogen INC | $23.35 | 2025 | Teriparatide |
| Celltrion USA INC. | $22.75 | 2023 | Yuflyma |
| Redhill Biopharma INC. | $19.96 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.56 | 2021 | |
| Pacira Therapeutics, INC. | $17.94 | 2020 | |
| Neuronetics, INC. | $15.71 | 2019 | |
| Medexus Pharma, INC. | $14.31 | 2019 | |
| Mallinckrodt Enterprises LLC | $11.27 | 2019 | |
| Gilead Sciences, INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Kieval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.